On May 6, 2024, Novo Nordisk A/S, a leading global healthcare company, announced the initiation of a new share repurchase programme. The programme, which is part of a larger DKK 20 billion repurchase plan for 2024, allows for the buyback of up to DKK 2.2 billion worth of shares. This move is aimed at reducing the company's share capital and fulfilling obligations from share-based incentive programmes. The repurchase of B shares, each with a nominal value of DKK 0.10, will commence on May 7, 2024, and is set to conclude by August 5, 2024. Novo Nordisk has set a cap of 350 million B shares for the repurchase within this period. The company, with a rich history dating back to 1923 and a workforce of approximately 66,000 across 80 countries, is committed to combating serious chronic diseases and has a strong presence in the global market with products available in around 170 countries.

On May 6, 2024, Novo Nordisk A/S, a leading global healthcare company, announced the initiation of a new share repurchase programme. The programme, which is part of a larger DKK 20 billion repurchase plan for 2024, allows for the buyback of up to DKK 2.2 billion worth of shares. This move is aimed at reducing the company's share capital and fulfilling obligations from share-based incentive programmes. The repurchase of B shares, each with a nominal value of DKK 0.10, will commence on May 7, 2024, and is set to conclude by August 5, 2024. Novo Nordisk has set a cap of 350 million B shares for the repurchase within this period. The company, with a rich history dating back to 1923 and a workforce of approximately 66,000 across 80 countries, is committed to combating serious chronic diseases and has a strong presence in the global market with products available in around 170 countries.